U.S. Colorectal Cancer Screening Market Trends

• The shift towards a preventive healthcare approach: The shift towards a preventive healthcare approach is indeed a key trend in the U.S. colorectal cancer screening market. This trend towards preventive care is driven by the understanding that it is more effective to prevent disease or detect it early rather than to treat it once it has progressed. There is an increasing emphasis on the early detection of colorectal cancer, as outcomes are typically better when the disease is diagnosed at an earlier stage. Preventive screenings like colonoscopies, FIT tests, and stool DNA tests can detect precancerous polyps or early-stage cancers before symptoms appear. Medical guidelines now recommend earlier screening for colorectal cancer, with some suggesting that screening begin at age 45 instead of 50 for average-risk individuals. This change in recommendations is reflective of the move towards a preventive healthcare approach. Governmental public health organizations and private groups are actively promoting awareness about the importance of regular colorectal cancer screening, highlighting its role in preventing cancer and improving survival rates. Preventive screenings, including those for colorectal cancer, are often covered without out-of-pocket costs under many health insurance plans, including the Affordable Care Act, encouraging more people to undergo routine screenings. Advances in screening technologies are making it easier and more convenient to perform preventive screenings. For example, home-based FIT kits and other non-invasive methods broaden access to preventive care

U.S. Colorectal Cancer Screening Market- Regional Insights

• Northeast: Northeast region is the largest colorectal cancer market in the U.S., with a market share of over 40%. The region is home to some of the largest and most affluent cities in the US, as well as a number of major pharmaceutical companies.
• West: The West region is the second-largest colorectal cancer in the US, with a market share of over 30%. The region is home to a number of large and growing cities, as well as a number of biotech companies.
• South: The South region is the third-largest colorectal cancer in the US, with a market share of over 15%. The region is home to a number of large and growing cities, as well as a number of pharmaceutical companies.
• Midwest: The Midwest region is the smallest colorectal cancer in the US, with a market share of under 15%. The region is home to a number of large and growing cities, but it also has a number of rural areas.

Figure 1.  U.S. Colorectal Cancer Screening Market Value (US$ Bn), 2023